Results from the PROMINENT trial will offer insights into the cardiovascular benefit of the selective PPARα agonist pemafibrate, where data on histological outcomes in NAFLD are currently lacking. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.